International Assets Investment Management LLC Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

International Assets Investment Management LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 673 shares of the biopharmaceutical company’s stock after selling 102 shares during the period. International Assets Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $591,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in REGN. Drive Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 12 shares during the last quarter. Sutton Wealth Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares in the last quarter. Clearview Wealth Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 13 shares during the last quarter. Smithfield Trust Co lifted its position in shares of Regeneron Pharmaceuticals by 11.0% during the third quarter. Smithfield Trust Co now owns 141 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 14 shares during the last quarter. Finally, Simon Quick Advisors LLC grew its stake in Regeneron Pharmaceuticals by 3.2% in the fourth quarter. Simon Quick Advisors LLC now owns 449 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 14 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ:REGN opened at $982.29 on Monday. The firm has a 50 day simple moving average of $942.68 and a 200 day simple moving average of $909.82. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The company has a market cap of $108.24 billion, a PE ratio of 29.02, a price-to-earnings-growth ratio of 2.02 and a beta of 0.17.

Insider Activity

In related news, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Marion Mccourt sold 358 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $967.50, for a total transaction of $346,365.00. Following the completion of the sale, the executive vice president now directly owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The disclosure for this sale can be found here. Insiders sold 55,925 shares of company stock worth $54,616,836 over the last quarter. Corporate insiders own 8.83% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on REGN. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective on the stock. Truist Financial restated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. UBS Group raised their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $989.36.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.